Top Markets
Coin of the day
Nuformix plc Nuformix plc

Nuformix plc

NFX
Rank in Stocks #20651
Nuformix plc operates in the field of pharmaceutical development for treating... Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.
Share Price
$0.00244926
Market Cap
$51.67K
Change (1 day)
5.88%
Change (1 year)
110.15%
Country
GB
Trade Nuformix plc (NFX)

Category

Earnings for Nuformix plc (NFX)
Earnings in Sep 2025 TTM: $-5.28M
According to Nuformix plc latest financial reports the company's current earnings are $-5.28M. In 2024 the company made an earning of $-4.88M, a decrease compared to its 2023 earnings that were of $-754.56K. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Nuformix plc from 2014 to 2026
Earnings at the end of each year
Year Earnings Change
2026 (TTM) $-5.28M 494.63%
2025 $-888.01K -81.80%
2024 $-4.88M 546.72%
2023 $-754.56K -54.82%
2022 $-1.67M -11.94%
2021 $-1.90M 64.37%
2020 $-1.15M -51.92%
2019 $-2.40M -12.87%
2018 $-2.75M 220.48%
2017 $-859.40K 70.68%
2016 $-503.51K -206.04%
2014 $474.83K 0.00%
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
$20.46B -387,521.89%
DK
$4.64B -88,033.93%
US
$5.23B -99,160.13%
US
$2.14B -40,584.12%
BE
$1.61B -30,671.66%
AU